Antiphospholipid antibody syndrome: Why and how should we make the diagnosis?;Syndrome des antiphospholipides: Pourquoi faut-il y penser et comment faire le diagnostic?

Revue du Rhumatisme (Edition Francaise)

Volumn 70, Issue 3, 2003, Pages 228-234

  Sibilia, Jean ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Antiphospholipid antibodies; Autoantibodies; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; LIPOCORTIN 5; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID ANTIBODY; PLASMA PROTEIN;

ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; HUMAN; PROPHYLAXIS; REVIEW; RISK FACTOR; THROMBOGENICITY; THROMBOPHILIA; THROMBOSIS;

EID: 4444314439     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(03)00057-7     Document Type: Short Survey

References (54)

1. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31:621.
2. Hazerick JR, Long R. Systemic lupus erythematosus preceded by false-positive serologic tests for syphylis: presentation of 5 cases. Ann Intern med 1952;37:559-65.
3. Moore JE, Mohr CF. Biologically false positive serological tests for syphilis, Type, incidence and cause. J Am Med Assos 1952;150:467-75.
4. Bowie WE, Thompson JM, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulant. J Clin Invest 1963;62:416-30.
5. Nilsson IN. Intrauterine death and circulating anticoagulant. Acta Med Scand 1975;197:153-9.
6. Soulier JP, Boffa MC. Avortements à répétition, thrombose, anticoagulant circulant. Nouv Presse Med 1980;9:859-65.
7. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in SLE. Lancet 1983;2:1211-4.
8. Hughes GRV. Thrombosis abortion, cerebral disease and lupus anticoagulant. Br Med J 1983;287:1088-9.
9. Gomez JA, Martin H, Amigo MC, Aguirre MA, Guadrado MJ, et al. Long-term follow-up in 90 patients with primary antiphospholipid syndrome, Do they develop lupus? Arthritis Rheum 2001;44:S146 (Abst 562).
10. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Auto-immun 2000;15:145-51.
11. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
12. Wahl G, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying auto-immune disease or previous thrombosis. Lupus 1998;7:15-225.
13. Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea in the antiphospholipid syndrome, Clinical, radiologie and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997;76:203-12.
14. Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002;61:195-8.
15. Karmochkine M, Cacoub P, Dorent R, Laroche P, Nataf P, Piette JC, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996;23:286-90.
16. Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998;59:20-3.
17. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996;5:442-7.
18. Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997;103:33-7.
19. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001;80:355-77.
20. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358-61.
21. Tamura N, Kobayashi S, Hashimoto H. Anticardiolipin antibodies in patients with post-streptococcal reactive arthritis. Ann Rheum Dis 2002;61:374.
22. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti-β2-glycoprotein I and anti-prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008-14.
23. Horbach DA, Van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus, Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24.
24. Gomez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcon-Segovia D. Serum anti-β2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999;106:417-23.
25. Wahl DG, de Maistre E, Guillemin F, Regnault V, Perret-Guillaume C, Lecompte T. Antibodies against phospholipids and beta-2-glycoprotein I increase the risk of recourent venous thromboembolism in patients without systemic lupus erythematosus. QJM 1998;91:125-30.
26. Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral AR. The antiphospholipid/cofactor syndromes, II. A variant in patients with systemic lupus erythematosus with antibodies to β2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 1997;24:1545-51.
27. Gris JC, Quere I, Sanmarco M, Boutiere B, Mercier E, Amiral A, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, nonautoimmune women with unexplained recurrent primary early fœtal loss. Thromb Haemost 1998;79:282-5.
28. Sanmarco M, Alessi MC, Harle JR, Sapin C, Aillaud MF, Gentile S, et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001;85:800-5.
29. Mc Intyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine antibodies: a survey. J Autoimmun 2000;15:185-93.
30. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93.
31. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
32. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997;337:154-60.
33. Rand JH. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J Autoimmun 2000;15:107-11.
34. Alarcon-Segovia D, Perez-Vasquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Sem Arthritis Rheum 1992;21:275-85.
35. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
36. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440-3.
37. Weber M, Hayem G, Meyer O. The Sapporo criteria for antiphospholipid syndrome: comment on the article by Lockshin et al. Arthritis Rheum 2001;44:1965-6.
38. Gharavi AE, Pierangeli SS, Harris EN. New developments in viral peptides and APL induction. J Autoimmun 2000;15:227-30.
39. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of antibodies to beta 2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002;109:797-804.
40. Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the ninth international (Tours) APL symposium. Lupus 2001;10:457-60.
41. Deschiens MA, Conard J, Horellou MH, Ameri A, Preter M, Chedru F, et al. Coagulation studies, factor V Leiden and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-30.
42. Galli M, Finazzi G, Duca F, Norbis F, Moia M. The G1691 → A mutation of factor V, but not the G20210 → A mutation of factor II or the C677 → T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000;108:865-70.
43. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch 3 mutations in Casadil, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10.
44. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A descision analysis. Arch Intern Med 2000;160:2042-8.
45. Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 years follow-up of 52 patients. Lupus 1998;7:3-6.
46. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after foetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001;44:1466-7.
47. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995;332:993-7.
48. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy, Duration of Anticoagulation Study Group. Am J Med 1998;104:332-8.
49. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of 3 months of anticoagulation with extended anticoagulation for a 1st episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
50. Douketis JD, Crowther MA, Julian JA, Stewart K, Donovan D, Kaminska EA, et al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost 1999;82:1028-32.
51. Brunner HI, Chan WS, Ginsberg JS, Feldman BM. Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome, result of a decision analysis. J Rheumatol 2002;29:490-501.
52. Castellino G, Cuadrado MJ, Godfrey T, Khamashta MA, Hughes GRV. Characteristics of patients with antiphospholipid syndrome with major bleedingafter oral anticoagulant treatment. Ann Rheum Dis 2001;60:527-30.
53. Girardi G, Pierangeli S, Holers VM, Espinola R, Lui X, Harris N, et al. Complement activation is required for antiphospholipid antibody-induced thrombosis. Arthritis Rheum 2001;44(suppl):S162 Abst 660.
54. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997;96:4380-4.